Welcome to MM&MLive@Cannes, Year Deux!
MM&M's Live@Cannes returns for year two of the Lions Health International Festival of Creativity. Here you'll find daily coverage of the latest trends, themes and chatter around creativity in healthcare, live from the south of France during the two-day festival. Pre-conference coverage starts Monday, June 1, 2015.
The first of seven games aimed at teaching about immuno-oncology lets players fling antibodies at cancer cells.
The new OTC medication almost hit $100 million in sales in its first 16 weeks on the market.
Bristol-Myers Squibb's Opdivo serves up lukewarm lung-cancer results; new cancer drugs are too expensive, Sloan Kettering oncologist tells ASCO attendees; Teva settlement could stymie industry use of pay-for-delay patent tactics
Perhaps the best testament to Commissioner Hamburg's tenure is that crises were uniformly handled responsibly
In Jack Welch's view, one of the worst mistakes a manager can make is . . .
Are You Looking at ME?
Healthcare professionals' customer experiences are increasingly being shaped by retailers like Amazon and Zappos. What ideas should drugmakers borrow from them to personalize promotion and what are the limits?
The submissions to the MM&M Awards are closed and the fun—and the hours of work—have begun for our judges. As is the case every year, the 2015 panel is a group of esteemed leaders, thinkers and experts who represent a wide range of disciplines within pharma, biotech, devices and diagnostics, agencies and media companies. Their efforts will determine which agencies take home the gold on October 1 in New York City
Pharma companies have long struggled to pen compelling value stories for their products. Could they learn a thing or two from the case Keryx Pharmaceuticals built for its renal drug Auryxia? James Chase reports
Click the link below to access the Digital Edition of MM&M's Patient Journeys 2015, with all text, charts and pictures.
Amgen prepares for pricing battle over PCSK9-inhibitor Repatha; Otsuka loses Abilify lawsuit; healthcare and pharma marketers will boost spending on digital advertising in 2015
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.